Since K-ras mutations are detected in most of pancreatic adenocarcinoma lesions [1], it led us to examine the susceptibility of pancreatic cancer cells to apoptosis in response to the treatment with GO6976 (a PKC inhibitor specific for PKC α and β). The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.